NCT04597905

Paricipant Preferences in the Treatment of Inflammatory Bowel Disease (IBD) in Europe

Observational Study to Define Patient Preferences Toward the Attributes of Treatment Used for Inflammatory Bowel Disease, Including Efficacy Profile, Safety Profile, Frequency and Route of Administration, in Europe

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 686 (actual)
• Sponsor: Takeda · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this survey is to describe Crohn's disease (CD) participants' as well as ulcerative colitis (UC) participants' preferences towards the attributes of treatment with advanced therapies for IBD, including safety and efficacy profiles, frequency and route of administration (RoA) in a real-world setting.

Detailed description

This is a descriptive, observational, cross-sectional survey of participants with IBD. The survey will look into the preferences of participants towards the attributes of treatment with advanced therapies for IBD based on DCE (experimentally designed survey), including safety and efficacy profiles, frequency and RoA in a real-world setting, in European participants living with CD or UC. The survey will involve data collection in a real-world setting via an online self-reported questionnaire hosted on the Carenity platform, an international participant community. The survey will enroll approximately 600 participants. Participants will be enrolled in two observational cohorts: * CD Participants * UC Participants This multi-center trial will be conducted in France, the United Kingdom, Italy, Spain, Belgium, Switzerland, the Netherlands.

Conditions

• Crohn Disease
• Colitis, Ulcerative
• Inflammatory Bowel Diseases

Timeline

• Start date: 2020-10-21
• Primary completion: 2021-01-31
• Completion: 2021-01-31
• First posted: 2020-10-22
• Last updated: 2021-02-11

Locations

1 site across 1 country: France